RecruitingNCT06562777
Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer
INvestigating Sex and Gender-Related Differences in Immunotherapy Treatment Effects (INSITE)
Sponsor
OHSU Knight Cancer Institute
Enrollment
100 participants
Start Date
Sep 15, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to learn more about symptoms that patients experience while receiving immunotherapy for cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying Non-Interventional Study for people with hematopoietic and lymphatic system neoplasm and malignant solid neoplasm. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-Interventional Study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06562777
Related Trials
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT06126276188 locations
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
NCT04242095625 locations
Different Types of Massage Therapy to Reduce Anxiety During Chemotherapy Infusion in Patients With Cancer
NCT071842941 location
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT0381634552 locations
A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
NCT061928751 location